Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Apr 29;6(4):e18885. doi: 10.1371/journal.pone.0018885

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

PMC Copyright notice

Allograft recipients were monitored for cardiac viability through the 28-day post-transplant period of observation. Rejection and engraftment control cohorts received a 10-day short-course of cyclosporine A [“CSA(10]” or a daily 28-day course of “CSA [CSA(28)”]. Other cohorts received either no cyclosporine A or short-course CSA(10) in combination with Th2.R cell therapy at day −7 [“Th2.R(D-7)” or “CSA(10)+Th2.R(D-7)”], day 0 [“Th2.R(D0)” or “CSA(10)+Th2.R(D0)”], or day −7 plus day 0 [“Th2.R(D-7+D0)” or “CSA(10)+Th2.R(D-7+DO)”]. (a) Hematoxylin and eosin staining was performed at day 28 post-transplant. Left panels show a representative example of severe allograft rejection in recipients of short-course CSA(10) alone (characterized by diffuse inflammation and necrosis); right panels show a representative example of relatively preserved myocardial cell structure and reduced mononuclear cell infiltration in recipients of short-course CSA(10) therapy plus Th2.R cell therapy. (b) Cumulative histology score between various cohorts is shown. I = isograft, A = Allograft; IHC score = Immunohistochemistry score.